Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

But that doesn’t necessarily threaten the market dominance of Keytruda, a top Merck executive said — and some analysts agree. “I see these results as important, but preliminary,” Merck ...

At the European Society for Medical Oncology Congress on September 13–17, promising results from the Phase III KEYNOTE-522 study involving MSD's neoadjuvant Keytruda (pembrolizumab) plus ...

Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 trial with chemoradiotherapy in patients with cervical cancer, cutting ...

Charlie CY Yang has given his Buy rating due to a combination of factors, including the strong performance and potential of Merck’s key products, particularly Keytruda and Gardasil. The growth ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...